Xylem (XYL) stock is back in focus after Jefferies upgraded the company and Xylem announced a major water systems agreement with Dow in Alberta, tying the business more closely to a large sustainability project.
See our latest analysis for Xylem.
At a share price of $118.12, Xylem has seen a 7.44% 1 month share price return but is still down 13.85% year to date, while the 1 year total shareholder return has declined 9.55%, suggesting recent momentum is improving from a weaker stretch.
As you weigh Xylem’s latest moves in water infrastructure and treatment, it can also be useful to see what else is gaining traction across power grid technology and infrastructure stocks via the 35 power grid technology and infrastructure stocks.
With Xylem now trading at $118.12, carrying an intrinsic discount of roughly 13% and a sizeable gap to the average analyst price target, the key question is whether the recent rebound still leaves room for upside or if the market is already pricing in future growth.
Most Popular Narrative: 21.6% Undervalued
Compared with Xylem’s last close at $118.12, the most followed narrative points to a fair value closer to the mid $150s, built on specific growth, margin and valuation assumptions.
Significant and increasing investment in aging water infrastructure (notably in the U.S. and U.K.) underpins a strong multi-year backlog (> $5 billion), with anticipated order rebounds as funding cycles and regulatory timelines normalize, supporting steady revenue growth and greater earnings visibility.
Curious what kind of revenue profile and margin uplift this narrative is leaning on. The crux is a higher earnings base supported by a premium P/E multiple. It will be useful to see which specific growth, profitability and discount rate inputs support that $150.65 fair value mark.
Result: Fair Value of $150.65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points, including reliance on government funded water projects and the execution risk around integrating acquisitions like Evoqua, that could undermine the Xylem narrative.
Find out about the key risks to this Xylem narrative.
Another View on Xylem Using Market Multiples
The first narrative leans on detailed forecasts and a discounted cash flow style fair value of $150.65 for Xylem. By contrast, the current P/E of 28.6x is slightly higher than the US Machinery industry at 27.9x and very far below peers at 41.3x. This points to mixed signals on how much valuation risk or opportunity may exist here.
With the current P/E also very close to the fair ratio of 28.9x, the market is pricing Xylem almost exactly in line with what regression based models suggest it could move toward. The real question is whether future earnings are strong enough to justify any further re rating.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Xylem mixed but improving, this is a moment to look directly at the underlying data and quickly shape your own view. To see what investors are optimistic about right now, review the 5 key rewards.
Looking for more investment ideas beyond Xylem?
If Xylem has caught your attention, do not stop here. Broaden your watchlist with other focused ideas that could sharpen your overall portfolio decisions.
- Spot potential value opportunities early by running through the screener containing 18 high quality undiscovered gems that may still be flying under the radar.
- Strengthen the quality of your core holdings by checking companies in the solid balance sheet and fundamentals stocks screener (47 results) with fundamentals that can support long term plans.
- Aim for a smoother ride by reviewing the 74 resilient stocks with low risk scores that meet tighter risk criteria before they draw wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com